The study intends to assess CF33-CD19 alone or combined with blinatumomab (a bispecific CD19-directed CD3 T-cell engager [BiTE] specific to CD19 and CD3).. Credit: Meletios Verras via Shutterstock.com.

The US Food and Drug Administration (FDA) has granted clearance to Imugene’s investigational new drug (IND) application for initiating a Phase I clinical trial of onCARlytics (on-CAR-19, CF33-CD19, HOV4), its oncolytic virotherapy candidate, to treat advanced or metastatic solid tumours.

A live, attenuated oncolytic orthopox (vaccinia) virus, CF33-CD19 encodes a truncated human CD19 transgene resulting in de novo CD19 expression at the tumour cell surface before virus-mediated tumour cell lysis.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The clearance allows Imugene to enrol and dose patients with advanced or metastatic solid tumours in its first-in-human (FIH) dose escalation study.

To be conducted in the US, the study intends to assess the efficacy and safety of CF33-CD19 alone or combined with blinatumomab (a bispecific CD19-directed CD3 T-cell engager [BiTE] specific to CD19 and CD3).

The treatment will be administered to patients by either intratumoral (IT) injection or intravenous (IV) infusion.

See Also:

Imugene MD and CEO Leslie Chong said: “The start of our onCARlytics study, which is first-in-class, is a significant milestone for clinicians treating patients faced with the challenge of solid tumour cancers, which to date have been untreatable with CD19- targeting biological drugs.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Accomplishing this goal speaks to the perseverance and dedication of Imugene’s and City of Hope’s research and development teams as we continue to build on our clinical and commercial potential.”

Last May, Imugene along with City of Hope dosed the first subject in Phase I study of a new cancer-killing virus, CF33-hNIS (Vaxinia), in patients with advanced solid tumours.